BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

...Kite CSO David Chang.Nextech and Vida Ventures led the round. Belldegrun holds leadership positions at Vida, Two River...
...all of which invested. Chang, who is IconOVir’s chairman, also holds positions at Vida and Two River...
...Calif.Technology: Next-generation oncolytic virusesOrigin of technology: Salk InstituteDisease focus: CancerClinical status: PreclinicalFounded: July 2020 by Two River...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...participation from Polaris Partners and Pontifax as well as seed investors Vida Ventures, TPG and Two River. ...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...Inc.’s untranched round, as did new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...LLC, Gilead Sciences Inc. (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Regents of the University of California , Two River...
BioCentury | Sep 20, 2018
Emerging Company Profile

Recalcitrant Targets

...molecule microarray platform for compound screening Disease focus: Cancer Clinical status: Preclinical Founded: 2017 by Two River...
...employees: 8 Funds raised: $18 million Investors: BellCo Capital, John Martin, Norbert Bischofberger, Omega Funds, Two River...
BioCentury | May 25, 2018
Financial News

Kronos raises $18M seed round, names Bischofberger CEO

...CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until April. Two River...
BioCentury | May 23, 2018
Financial News

Kronos raises seed round, names Bischofberger CEO

...CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until April. Two River...
BioCentury | Apr 6, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...of the Chief Investment Officer, Pfizer and other undisclosed investors participated. Life science investment firm Two River...
BioCentury | Apr 3, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...of the Chief Investment Officer, Pfizer and other undisclosed investors participated. Life science investment firm Two River...
BioCentury | Jul 18, 2016
Financial News

Sienna Biopharmaceuticals financial update

...to $46 million. Existing investors Arch Venture Partners and Partner Fund Management and new investor Two River...
Items per page:
1 - 10 of 14
BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

...Kite CSO David Chang.Nextech and Vida Ventures led the round. Belldegrun holds leadership positions at Vida, Two River...
...all of which invested. Chang, who is IconOVir’s chairman, also holds positions at Vida and Two River...
...Calif.Technology: Next-generation oncolytic virusesOrigin of technology: Salk InstituteDisease focus: CancerClinical status: PreclinicalFounded: July 2020 by Two River...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...participation from Polaris Partners and Pontifax as well as seed investors Vida Ventures, TPG and Two River. ...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...Inc.’s untranched round, as did new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...LLC, Gilead Sciences Inc. (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Regents of the University of California , Two River...
BioCentury | Sep 20, 2018
Emerging Company Profile

Recalcitrant Targets

...molecule microarray platform for compound screening Disease focus: Cancer Clinical status: Preclinical Founded: 2017 by Two River...
...employees: 8 Funds raised: $18 million Investors: BellCo Capital, John Martin, Norbert Bischofberger, Omega Funds, Two River...
BioCentury | May 25, 2018
Financial News

Kronos raises $18M seed round, names Bischofberger CEO

...CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until April. Two River...
BioCentury | May 23, 2018
Financial News

Kronos raises seed round, names Bischofberger CEO

...CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until April. Two River...
BioCentury | Apr 6, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...of the Chief Investment Officer, Pfizer and other undisclosed investors participated. Life science investment firm Two River...
BioCentury | Apr 3, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...of the Chief Investment Officer, Pfizer and other undisclosed investors participated. Life science investment firm Two River...
BioCentury | Jul 18, 2016
Financial News

Sienna Biopharmaceuticals financial update

...to $46 million. Existing investors Arch Venture Partners and Partner Fund Management and new investor Two River...
Items per page:
1 - 10 of 14